ArticleAnnals of hematology2026
Possible CPX-351-associated drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome-like reaction during severe lymphopenia.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug reaction with eosinophilia and systemic symptoms (DRESS), also known as drug-induced hypersensitivity syndrome (DIHS), is a severe delayed drug reaction characterized by skin eruption, systemic inflammation, organ involvement, and human herpesvirus 6 (HHV-6) reactivation. CPX-351 is increasingly used for high-risk acute myeloid leukemia, and skin eruptions are common adverse events; however, CPX-351-associated DRESS/DIHS-like reactions have not been well described. We report a 62-year-old man with acute erythroid leukemia who developed a progressive eruption after CPX-351 therapy. An early intertriginous and truncal eruption was initially compatible with toxic erythema of chemotherapy (TEC), whereas subsequent recurrent fever, generalized erythema involving more than 90% of the body surface area, lymphadenopathy, atypical lymphocytes, liver enzyme elevation, and marked HHV-6 DNA elevation (1.2 × 10
Indexed as
Identifiers
42878768What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.